Maravai Lifesciences Holdings (MRVI) Gross Margin (2020 - 2026)
Maravai Lifesciences Holdings' (MRVI) quarterly Gross Margin came in at 51.19% in Q1 2026, up 3470.0% year-on-year from 1.43% in Q1 2025, and up 98.77% quarter-over-quarter from 25.75% in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Gross Margin (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Gross Margin history runs 7 years deep, the most recent figure standing at 51.19% for Q1 2026.
- On a quarterly basis, Gross Margin rose 3470.0% year-over-year to 51.19% in Q1 2026; TTM through Mar 2026 was 29.29%, a 800.0% decrease from a year earlier, with the FY2025 full-year figure at 18.3%, down 2349.0% from the prior year.
- Gross Margin improved to 51.19% in Q1 2026 per MRVI's latest filing, from 25.75% in the prior quarter.
- Across five years, Gross Margin topped out at 84.55% in Q2 2022 and bottomed at 13.58% in Q3 2025.
- The 5-year median for Gross Margin is 45.13% (2023), against an average of 47.27%.
- Across the five-year window, Gross Margin slumped 4735 bps in 2023 and soared 3470 bps in 2026, its largest moves.
- Year by year, Gross Margin stood at 73.99% in 2022, then declined by 29 bps to 52.65% in 2023, then tumbled by 35 bps to 34.28% in 2024, then declined by 25 bps to 25.75% in 2025, then soared by 99 bps to 51.19% in 2026.
- Per Business Quant, the three latest MRVI Gross Margin figures stand at 51.19% (Q1 2026), 25.75% (Q4 2025), and 13.58% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Maravai Lifesciences Holdings | 1.03 Bn | 1.02 Bn | 33.70 Mn | 51.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.19% |
| Dec 31, 2025 | 25.75% |
| Sep 30, 2025 | 13.58% |
| Jun 30, 2025 | 16.39% |
| Mar 31, 2025 | 16.49% |
| Dec 31, 2024 | 34.28% |
| Sep 30, 2024 | 46.70% |
| Jun 30, 2024 | 44.42% |
| Mar 31, 2024 | 40.27% |
| Dec 31, 2023 | 52.65% |
| Sep 30, 2023 | 45.13% |
| Jun 30, 2023 | 37.21% |
| Mar 31, 2023 | 57.39% |
| Dec 31, 2022 | 73.99% |
| Sep 30, 2022 | 80.04% |
| Jun 30, 2022 | 84.55% |
| Mar 31, 2022 | 83.61% |
| Dec 31, 2021 | 82.87% |
| Sep 30, 2021 | 84.27% |
| Jun 30, 2021 | 82.64% |